The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables.
about
Bronchodilator responsiveness and reported respiratory symptoms in an adult populationValidity of peak expiratory flow measurement in assessing reversibility of airflow obstructionClinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program.Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial.Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma.Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at restWorldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease studyEffects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airfloVariability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.The American Thoracic Society's spirometric criteria alone is inadequate in asthma diagnosis.Measures of bronchodilator response of FEV1, FVC and SVC in a Swedish general population sample aged 50-64 years, the SCAPIS Pilot Study.On the meaning and utility of diagnostic terms: Special reference to bronchopulmonary abnormalities in the horse.Predicted values: how should we use them?Bronchial responsiveness in patients with restrictive spirometry.
P2860
Q28488078-6B2249B0-3A69-4C31-8265-9D530108FA87Q33604390-2F257267-7D35-40E1-9525-A3046282DB5FQ34165210-7B5ABEFA-8276-4A39-B9BC-55229A63826FQ34521884-5E9E1656-219B-4596-BFE9-4C90368AFC16Q34961526-ACA75012-848A-4972-A920-E991FFF932D8Q35535208-3B668C66-6E77-4EE9-8FE8-487BA7389E0EQ36110451-670074DE-206B-4EE9-BD4C-EA2E3342BFC7Q36278212-5A34F34B-66D8-459E-8333-EC7E982D6C06Q36284291-C0320636-376D-4F1C-BFFB-EF1D2D743903Q37195346-FDF4496F-4BB9-4916-ABCE-CA100110BC44Q37722887-65721F2A-7EC0-45CE-8506-810A8FB4E43EQ40489155-2C9753E0-042D-47B8-A5A6-648184F40D3CQ41130291-9CD744B8-CD26-47E5-9A7B-F2047F5D83EDQ45728403-FCE06536-312E-4FAC-AF91-828D93501590
P2860
The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh-hant
name
The use of criteria for revers ...... and anthropometric variables.
@en
The use of criteria for revers ...... and anthropometric variables.
@nl
type
label
The use of criteria for revers ...... and anthropometric variables.
@en
The use of criteria for revers ...... and anthropometric variables.
@nl
prefLabel
The use of criteria for revers ...... and anthropometric variables.
@en
The use of criteria for revers ...... and anthropometric variables.
@nl
P1476
The use of criteria for revers ...... and anthropometric variables.
@en
P2093
Degraff AC Jr
Eliasson O
P304
P356
10.1164/ARRD.1985.132.4.858
P577
1985-10-01T00:00:00Z